|
1
|
Maron BJ, Gardin JM, Flack JM, Gidding SS,
Kurosaki TT and Bild DE: Prevalence of hypertrophic cardiomyopathy
in a general population of young adults. Echocardiographic analysis
of 4111 subjects in the CARDIA study. Coronary artery risk
development in (young) adults. Circulation. 92:785–789. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maron BJ and Maron MS: Hypertrophic
cardiomyopathy. Lancet. 381:242–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Semsarian C, Ingles J, Maron MS and Maron
BJ: New perspectives on the prevalence of hypertrophic
cardiomyopathy. J Am Coll Cardiol. 65:1249–1254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maron BJ: Contemporary insights and
strategies for risk stratification and prevention of sudden death
in hypertrophic cardiomyopathy. Circulation. 121:445–456. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maron BJ, Thompson PD, Ackerman MJ, Balady
G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter AM
Jr, et al: Recommendations and considerations related to
preparticipation screening for cardiovascular abnormalities in
competitive athletes: 2007 update: A scientific statement from the
American heart association council on nutrition, physical activity,
and metabolism: Endorsed by the American college of cardiology
foundation. Circulation. 115:1643–1655. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahmad F, Seidman JG and Seidman CE: The
genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet.
6:185–216. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Waldmüller S, Sakthivel S, Saadi AV,
Selignow C, Rakesh PG, Golubenko M, Joseph PK, Padmakumar R,
Richard P, Schwartz K, et al: Novel deletions in MYH7 and MYBPC3
identified in Indian families with familial hypertrophic
cardiomyopathy. J Mol Cell Cardiol. 35:623–636. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gersh BJ, Maron BJ, Bonow RO, Dearani JA,
Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, et
al: 2011 ACCF/AHA guideline for the diagnosis and treatment of
hypertrophic cardiomyopathy: executive summary: a report of the
American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. Circulation.
124:2761–2796. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Authors/Task Force members, ; Elliott PM,
Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege
AA, Lafont A, Limongelli G, et al: 2014 ESC guidelines on diagnosis
and management of hypertrophic cardiomyopathy: The task force for
the diagnosis and management of hypertrophic cardiomyopathy of the
European society of cardiology (ESC). Eur Heart J. 35:2733–2779.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maron BJ, Maron MS and Semsarian C: Double
or compound sarcomere mutations in hypertrophic cardiomyopathy: A
potential link to sudden death in the absence of conventional risk
factors. Heart Rhythm. 9:57–63. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang J, Wang Y, Zou Y, Sun K, Wang Z, Ding
H, Yuan J, Wei W, Hou Q, Wang H, et al: Malignant effects of
multiple rare variants in sarcomere genes on the prognosis of
patients with hypertrophic cardiomyopathy. Eur J Heart Fail.
16:950–957. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zou Y, Wang J, Liu X, Wang Y, Chen Y, Sun
K, Gao S, Zhang C, Wang Z, Zhang Y, et al: Multiple gene mutations,
not the type of mutation, are the modifier of left ventricle
hypertrophy in patients with hypertrophic cardiomyopathy. Mol Biol
Rep. 40:3969–3976. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Helms AS, Alvarado FJ, Yob J, Tang VT,
Pagani F, Russell MW, Valdivia HH and Day SM: Genotype-dependent
and -independent calcium signaling dysregulation in human
hypertrophic cardiomyopathy. Circulation. 134:1738–1748. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cam FS and Güray M: Hypertrophic
cardiomyopathy: Pathological features and molecular pathogenesis.
Anadolu Kardiyol Derg. 4:327–330. 2004.PubMed/NCBI
|
|
15
|
Wang L, Zuo L, Hu J, Shao H, Lei C, Qi W,
Liu Y, Miao Y, Ma X, Huang CL, et al: Dual LQT1 and HCM phenotypes
associated with tetrad heterozygous mutations in KCNQ1, MYH7,
MYLK2, and TMEM70 genes in a three-generation Chinese family.
Europace. 18:602–609. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guex N and Peitsch MC: SWISS-MODEL and the
Swiss-PdbViewer: An environment for comparative protein modeling.
Electrophoresis. 18:2714–2723. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Richards S, Aziz N, Bale S, Bick D, Das S,
Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al:
Standards and guidelines for the interpretation of sequence
variants: A joint consensus recommendation of the American college
of medical genetics and genomics and the association for molecular
pathology. Genet Med. 17:405–424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lopes LR, Zekavati A, Syrris P, Hubank M,
Giambartolomei C, Dalageorgou C, Jenkins S, McKenna W, Uk10k
Consortium, Plagnol V and Elliott PM: Genetic complexity in
hypertrophic cardiomyopathy revealed by high-throughput sequencing.
J Med Genet. 50:228–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang S, Zou Y, Fu C, Xu X, Wang J, Song L,
Wang H, Chen J, Wang J, Huan T and Hui R: Worse prognosis with gene
mutations of beta-myosin heavy chain than myosin-binding protein C
in Chinese patients with hypertrophic cardiomyopathy. Clin Cardiol.
31:114–118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Woo A, Rakowski H, Liew JC, Zhao MS, Liew
CC, Parker TG, Zeller M, Wigle ED and Sole MJ: Mutations of the
beta myosin heavy chain gene in hypertrophic cardiomyopathy:
Critical functional sites determine prognosis. Heart. 89:1179–1185.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Walsh R, Rutland C, Thomas R and Loughna
S: Cardiomyopathy: A systematic review of disease-causing mutations
in myosin heavy chain 7 and their phenotypic manifestations.
Cardiology. 115:49–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kelly MA, Caleshu C, Morales A, Buchan J,
Wolf Z, Harrison SM, Cook S, Dillon MW, Garcia J, Haverfield E, et
al: Adaptation and validation of the ACMG/AMP variant
classification framework for MYH7-associated inherited
cardiomyopathies: Recommendations by ClinGen's inherited
cardiomyopathy expert panel. Genet Med. 20:351–359. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Viswanathan SK, Sanders HK, McNamara JW,
Jagadeesan A, Jahangir A, Tajik AJ and Sadayappan S: Hypertrophic
cardiomyopathy clinical phenotype is independent of gene mutation
and mutation dosage. PLoS One. 12:e01879482017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guidelines for the diagnosis and treatment
for Chinese adult patients with hypertrophic cardiomyopathy.
Zhonghua Xin Xue Guan Bing Za Zhi. 45:1015–1032. 2017.(In Chinese).
PubMed/NCBI
|
|
25
|
Elliott PM, Gimeno JR, Tomé MT, Shah J,
Ward D, Thaman R, Mogensen J and McKenna WJ: Left ventricular
outflow tract obstruction and sudden death risk in patients with
hypertrophic cardiomyopathy. Eur Heart J. 27:1933–1941. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maron MS, Olivotto I, Betocchi S, Casey
SA, Lesser JR, Losi MA, Cecchi F and Maron BJ: Effect of left
ventricular outflow tract obstruction on clinical outcome in
hypertrophic cardiomyopathy. N Engl J Med. 348:295–303. 2003.
View Article : Google Scholar : PubMed/NCBI
|
